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PENGENALPASTIAN IN VITRO BAGI PENGAWAL ATUR RESEPTOR 
HDL, SR-B1 DARIPADA PRODUK HASILAN SEMULA JADI TERPILIH 
 
ABSTRAK 
 
 Aterosklerosis adalah keadaan di mana dinding arteri menebal akibat 
daripada pengumpulan dan pengekalan bahan-bahan lemak kerana ketiadaan fungsi 
penyingkiran lemak dan kolesterol oleh lipoprotein berketumpatan tinggi. SR-B1 
adalah reseptor permukaan sel yang memainkan peranan penting dalam metabolisme 
kolesterol melalui laluan pengangkutan kolesterol berbalik (PKB). Esei gen pelapor 
telah dihasilkan dengan menggunakan rantau penggalak gen SR-B1 sebagai sasaran 
gen untuk menguji tindakbalas daripada produk semula jadi. Sejumlah 16 ekstrak 
tumbuhan dan 11 ekstrak marin telah disaring menggunakan asai tersebut. Dua 
ekstrak , iaitu Andrographis paniculata (hempedu bumi) dan Trochus niloticus (siput 
cengkerang besar) menunjukkan aktiviti positif dalam penyaringan awal. Experimen 
seterusnya tidak dapat diteruskan untuk Trochus niloticus disebabkan sampel yang 
terhad dan variasi antara sampel yang dikumpulkan. Oleh sebab itu, kerja seterusnya 
hanya diteruskan untuk  Andrographis paniculata. Empat kompoun telah dihasilkan 
daripada ekstrak A.paniculata dan disaring menggunakan asai tersebut. 
Menggunakan kaedah transfeksi sementara ke atas sel, aktiviti kompoun-kompoun 
dalam meningkatkan aktiviti rantau penggalak SR-B1 telah dinilai. Kompoun yang 
menghasilkan keputusan positif telah dikenal pasti sebagai andrographolide 
berdasarkan spektroskopi NMR dan analisis jisim. Teknik semi- kuantitatif PCR dan 
analisis immunohistokimia telah digunakan untuk menentukan kesan 
andrographolide kepada reseptor SR-B1 dalam sel-sel HepG2. Penemuan ini telah 
disahkan lagi dengan melakukan asai Dil-HDL. Hasil daripada penyaringan awal 
xvii 
 
menunjukkan bahawa andrographolide merupakan  pengantara transaktivasi rantau 
penggalak SR-B1 secara berkadar dos. Analisis immunohistokimia dan kajian gen 
membuktikan bahawa reseptor SR-B1 dikawal-selia oleh andrographolide. Asai Dil-
HDL mensahkan lagi penghabisan HDL kolesterol dalam sel-sel HepG2 yang 
dijalankan oleh SR-B1 reseptor yang diaktifkan akibat rawatan andrographolide. 
Kesimpulannya, kajian ini menunjukkan bahawa andrographolide sebagai pengawal 
selia transkripsi SR-B1 dalam sel HepG2 dan mempunyai aktiviti anti- 
aterosklerosis. 
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IN VITRO IDENTIFICATION OF HDL RECEPTOR, SR-B1 REGULATOR 
FROM SELECTED NATURAL PRODUCTS 
 
ABSTRACT 
 
Atherosclerosis is a condition where the artery wall thickens as a result of 
the accumulation and retention of fatty materials due to an absent of adequate 
removal of fats and cholesterols by functional high density lipoprotein. SR-B1 is a 
cell surface receptor which plays a crucial role in cholesterol metabolism via reverse 
cholesterol transport (RCT) pathway. A reporter gene based assay was developed by 
implying the promoter region of SR-B1 gene as target gene to test extracts from 
natural products for the anti-atherosclerotic properties. Total of 16 plant extracts and 
11 marine extracts were screened using the developed assay. Two extracts, namely 
Andrographis paniculata (Hempedu bumi) and Trochus niloticus (Giant top shell 
snail) showed an distinguished activity in preliminary screening. The subsequent 
work was unable to proceed for Trochus niloticus due to insufficient samples and 
also the samples variation between collected batches. Therefore, works were only 
carried out using Andrographis paniculata due to its samples availability. Four 
compounds were isolated from A.paniculata and subjected to screening. Utilising 
transient transfection approach, the potent activity of  the compounds in elevating 
SR-B1 promoter activity was evaluated. The positive hit compound was identified as 
andrographolide based on NMR and mass spectroscopic analysis. Subsequently, 
semi-quantitative real time PCR and immunohistochemistry was employed to 
observe the effect of andrographolide on SR-B1 mRNA expression and its protein 
content in HepG2 cells respectively. These findings were further validated by 
performing Diotadecylindocarbocyanine-High Density Lipoprotein (Dil-HDL) 
xix 
 
uptake assay. The preliminary screening performed using transient transfection 
approach demonstrated that andrographolide mediated the trans-activation of SR-B1 
promoter, thereby increased the transcriptional activity of SR-B1 in dose dependent 
manner. Subsequently, immunohistochemistry and mRNA expression study 
illustrated the mRNA and the protein expressions of the SR-B1 was up-regulated by 
andrographolide. Similarly, the Dil-HDL assay further confirmed the HDL 
cholesterol efflux was significantly improved in andrographolide-treated HepG2 
cells. Conclusively, we have demonstrated andrographolide as a potential 
transcriptional up-regulator of SR-B1 in HepG2 cells and possesses anti-
atherosclerotic activity. 
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CHAPTER 1 
INTRODUCTION 
1.1 Research background 
 
 
 Atherosclerosis is the condition in which an artery wall thickens as a result of 
the accumulation and retention of fatty materials. This condition occurs due to absent 
of adequate removal of fats and cholesterols from blood circulation and wall of blood 
vessels (Acton et al.,1999). Atherosclerosis has become one of the leading killer 
diseases in most of the developing countries including Malaysia (Bao et al., 2009). 
Genetic factors such as diabetics and hypercholesterolemia as well as the 
environmental factors such as smoking and unhealthy diet highly correlated to the 
incidence of atherosclerosis (Sainani et al., 2008; Jamkhande et al., 2013). Although 
there are many advances in research in related areas, atherosclerosis still remains a 
major medical problem which resulted in disastrous clinical consequences such as 
heart attack. 
 
 Presently, there are many lipid-lowering drugs available in current market 
which are able to regulate the level of cholesterol content in the body. For example, 
statins, fibrates and niacins are well known lipid lowering drugs extensively used to 
treat various lipid-related diseases (Drexel, 2009; Pal, 2009). Despite various 
cholesterols lowering therapies are widely available in current market, the scenario 
of cardiovascular disease especially atherosclerosis remains as leading cause of death 
globally. If this scenario continuous, it may leads to more severe consequences 
which potently claim extremely huge number of lives. Therefore, this critical 
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situation has advocated an urgent need to discover an anti-atherosclerotic agent with 
robust effect to overcome the atherosclerotic event effectively. Additionally, 
invention of new therapeutics by targeting the clearance of existing or deposited 
cholesterols in body may eventually lead a way to healthier life and reduce the risk of 
coronary heart disease (CHD).  
 
 Reverse cholesterol transport (RCT) is a protective mechanism which plays a 
very important role in cholesterol metabolism and potently resist the incidence of 
atherosclerosis. This pathway mainly emphasises on disposal of excessive free 
cholesterol in blood stream with the presence of functional  high density lipoprotein 
(HDL) molecules (Fielding and Fielding, 1995). Interestingly, the active HDL uptake 
and the removal of cholesterols into liver cells is facilitated through the activation of 
a special receptor, scavenger receptor class B type 1 (SR-B1) (Chao et al., 2010). 
SR-B1 receptor binds to HDL with high affinity and mediates the uptake of 
cholesteryl esters from HDL into the liver for disposal (Yumiko et al, 2005, Bao et 
al, 2009). Focusing new strategies by targeting SR-B1 receptors may open a new 
therapeutic invention for the treatment of atherosclerotic cardiovascular disease. 
Therefore, in our study we focused on the regulation of SR-B1 gene to identify 
potential ligand from natural products which able to halt the progression of 
atherosclerosis without serious side effects.  
 
 
 Plant natural products such as medicinal plants or phytomedicines are widely 
used to treat various diseases including cardiovascular disease (CVD). 
Conventionally, the parts of the plants such as roots, flowers and fruits are used to 
treat many disorders (Tang and Halliwell, 2010). Past studies have shown that 
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research communities have documented many medicinal properties of plants in the 
ethnopharmacology field, including as anti-atherosclerotic agents (Kris-Etherton et 
al., 2002; Obute and Adubor, 2007). Besides that, there is a growing interest in 
marine natural products due to its incredible diversity and greatly rich in 
pharmaceutically active compounds (Stankevicins et al., 2008). There is still vast 
percentage of marine organisms unidentified or poorly explored by the researchers 
due to its poor accessibility (Bugni et al., 2008). Previous studies on marine 
organisms have proven that marine natural product exhibit a broad range of activities 
including cardiovascular disorders. Additionally, most of the secondary metabolites 
produced by marine organisms are very exclusive with distinctive structural features 
compared to other natural resources (Stankevicins et al., 2008). These factors direct 
our interest to discover potential industrial and medical applications from plant and 
marine natural products for cardiovascular disease especially atherosclerosis. 
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1.2 Objectives of the study  
As described earlier, the role of SR-B1 in mediating RCT is pivotal in reducing the 
progression of atherosclerosis. Therefore, the objectives of the study were 
 
1. to construct SR-B1 promoter based luciferase screening assay 
2. to screen and identify the potential candidate(s) from natural products that 
induce the transcriptional activity of SR-B1 promoter 
3. to validate the effect of the potential candidate(s) on SR-B1 via gene and 
protein  expression studies and lipid uptake assay. 
 
The study is important not only for advancing our understanding of the effects of 
natural products in regulating the transcriptional activity of the SR-B1 promoter, but 
in longer term, may also possibly lead to the identification of candidates for 
therapeutic intervention of the lipid related diseases. This will enable specific drugs 
to be designed based on identified target of the diseases and thereby benefits the 
community especially those are suffering from various cardiovascular disorders. 
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CHAPTER 2 
LITERATURE REVIEW 
 
 
2.1  Atherosclerosis 
 
 
 Atherosclerosis is a type of cardiovascular disorder (CVD) categorised as one 
of the non-communicable and chronic inflammatory diseases. The accumulation and 
retention of fatty materials results in formation of thrombosis and hemorrhage in 
arterial wall lead to atherosclerosis (Figure 2.1). As the percentage of blockage 
increased in artery, this condition ended in serious cardiovascular complications such 
as heart attack, stroke and also death due to insufficient supply of oxygen-rich blood 
to organs and other parts of body (Castelli et al., 1986; Robert, 2005). 
Atherosclerosis has become one of the leading killer diseases in most of the 
developed and developing countries including Malaysia (Margaret, 2010; Bao et al, 
2009). World Health Organisation (WHO) has estimated 17.3 million people died 
from CVDs in 2008 and over 80 % of CVD deaths worldwide take place in low- and 
middle-income countries. According to WHO forecast, more than 23 million people 
will die annually from CVDs by 2030 (http://www.who.int/cardiovascular_ 
diseases/en/). Apart from that, the National Health and Morbidity Survey (NHMS) 
conducted by the Institute of Public Health in 2011 reported that 35.1% that is about 
6.2 million of adults who are 18 years and above have hypercholesterolemia in 
Malaysia (National Health and Morbidity Survey, 2011). 
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Figure 2.1  Atherosclerosis (A) shows a normal artery with normal blood flow (B) 
shows an artery with developed atherosclerotic plaque (Source: 
http://www.medicalnewstoday.com/articles/247837.php) 
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 Cholesterol is a waxy, fat-like substance found in the cell membrane of all 
body tissues. It is very important to our body as it involves in many biochemical 
processes such as production of steroid hormones, vitamin D and some essential 
substances for food digestion. Cholesterol is insoluble in blood and transported in the 
circulatory system via carriers called lipoprotein. Lipoprotein can be classified into 2 
main groups, namely low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL) which involve in cholesterol metabolism by carrying the lipid components 
from and to the liver. The excessive LDL cholesterol presents in the blood stream 
initiates the built-up of atherosclerotic plaques at the inner wall of arteries, thereby 
causing narrowing of arterial wall and leading to progression of atherosclerosis (Pal, 
2009). Conversely, a high level of HDL is beneficial as it prevents the occurrence of  
atherosclerosis and also helps in regression of atherosclerotic condition.  
 
 Immune and inflammatory mediators are the major factors for the initiation 
and development of atherosclerosis. Various reports described atherosclerosis  as an 
inflammatory event due to its occurrence highly associated to numerous cellular and 
molecular pathways. The process of atherogenesis has explained in two different 
theories. The first theory is 'response to injury' which explains the injuries occurred 
in the endothelial lining promote the deposition of LDL cholesterol in the intimal 
space and undergo modification. The modified LDL molecule is recruits by  
monocyte-derived macrophages and re-localised become foam cells (Ross et al., 
1977; Ross, 1993). The second hypothesis is 'response to retention', which clarify the 
removal of modified LDL components by macrophages from the intimal space via 
scavenger receptors and become foamy (Williams and Tabas, 1995).  
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 Briefly, the accumulated LDL cholesterols in the intimal space of endothelial 
cells undergo modification by oxidation. As the result of oxidation process by some 
LDL-oxidative enzymes such as lipoxygenases, myeloperoxidase and NADPH 
oxidases, the LDL converted into oxidised form (Li and Glass, 2002). Subsequently, 
the expression of adhesion molecules, such as intracellular adhesion molecule, 
vascular cell adhesion molecule, E-selectin and P-selectin are enhanced by the 
activated endothelial cells. Adhesion molecules play key roles in the recruitment of 
monocytes in the arterial wall. P-selectin binds to P-selectin glycoprotein ligand-1 
presents on monocytes which allows the capturing, rolling and activation of 
monocytes (Elstad et al., 1995; Weyrich et al., 1995). According to Chandak et al. 
(2011), P-selectin and E-selectin play similar role in atherosclerosis progression. The 
recruitment of monocyte and its firm adhesion to the endothelial surface are facilitate 
by vascular cell adhesion molecule. Besides, the adhesion, spreading and migration 
of monocyte into the sub-endothelial space are mediate by intracellular adhesion 
molecule (Chandak et al., 2011). Endothelial cells and smooth muscle cells secrete 
macrophage colony-stimulating factor, which differentiates the monocytes into 
macrophages in the endothelial space. Upon conversion, the endothelial cells induce 
the expression of microphage-chemoattractant protein-1; produced by activated 
microphages, in the presence of oxidised LDL. Consequently, the oxidised LDL 
undergo lysosomal degradation producing free cholesterols which result in foamy 
macrophages. The accumulation of lipid-laden microphages (foam cells) in the 
arterial wall is the major trait of atherosclerosis (Li and Glass, 2002). 
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2.1.1 Atherosclerotic risk factors 
 
 Progression of atherosclerotic plaque is a complex process, influenced by 
various genetic and environmental risk factors. In human, genetic enzymatic 
dysfunction, dietary deficiency as well as other environmental risk factors such as 
smoking, high fat diet and infectious agents promote the development  of 
atherosclerotic lesions in humans (Sainani et al., 2008). 
 
 Elevated cholesterol level is an independent pioneer trait greatly contributes 
to the progression and incidences of atherosclerosis (Sarah and Bruce, 2009). 
Cholesterol is an important substance to our body for the production of hormones 
and bile acids. However, the poor management of cholesterol due to impaired 
metabolic systems or pathways leads to hypercholesterolemia. This condition 
exaggerates the formation of plaques due to the deposition of excessive free and 
oxidised cholesterols along blood vessels (Yun et al., 2005). 
 
 The high sugar level in diabetes patients, especially type 2 diabetes patients 
often leads to atherosclerotic development. This complication resulted in more than 
80 % in overall diabetic death (Sainani et al., 2008). The enzymatic dysfunction in 
diabetes patients causes elevated level of LDL and triglycerides level, lessen the 
amount of HDL in plasma as well as promotes coronary calcification which  are 
directly correlated to the risk of CHD (Bradford and Thomas, 2002; Sarah and Bruce, 
2009). Consequently, diabetes represents as a major threat of atherosclerotic event 
globally (Yun et al., 2005). 
10 
 
 Smoking is one of the environmental jeopardize factor which greatly 
aggravates and speeds up the growth of atherosclerotic lesions in the blood vessels. 
Cigarette smoke boost the arterial wall stiffness by shooting up the fibrinogen level, 
hematocrit and platelet aggregation, thus eventually decreases  HDL level (Spence, 
2007; Keaney, 2000; Sarah and Bruce, 2009). According to Surgeon General update 
report, smoking enhances atherosclerotic disease by more than 50 % and increases 
the occurrences of CHD by two fold high (Keaney, 2000). The dissimilarities in 
genetic variants between individuals also related to the high risk of atherosclerosis in 
smokers compared to non-smokers (Bradford and Thomas, 2002). 
 
 
 
 
 
 
 
 
 
 
 
11 
 
2.2  Reverse Cholesterol Transport  
 
 Reverse cholesterol transport (RCT) is a principal protective system that 
plays a pivotal role in reducing the progression of atherosclerosis. It is referred to the 
opposing movement of cholesterol from peripheral region to the liver (Figure 2.2) 
and steroidogenic organs (Schoonjans et al., 2002).  
 
 The primary step in RCT is the removal of cholesterols from lipid laden cells 
found in the arterial wall. High density lipoprotein (HDL) plays a crucial role in the 
clearance of excessive cholesterols from extracellular matrixes. Approximately 70 % 
of HDL comprised of apoA-1 triggers the cholesterol efflux in the cells via RCT. The 
interaction of apoA-1 with ATP binding membrane cassette transport protein A1 
(ABCA1) present on the cell surface of lipid laden cells initiates the lipid 
mobilization (Wang et al., 2007a). Upon activation, the functional HDL recruits 
unesterified and free cholesterols from extra hepatic tissues. The recruited lipid 
substances will undergo esterification by lecithin-cholesterol acyltranferase (LCAT)  
on HDL forming cholesteryl esters (CE), eventually resulting in nascent HDL due to 
the increased amount of CE in this lipoprotein fraction. These larger HDL molecules 
able to interact with ATP binding membrane cassette transport protein G1 (ABCG1) 
and promote more lipid extraction from lipid-rich peripheral tissues (Wang et al., 
2007b). 
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Figure 2.2  Schematic diagram of reverse cholesterol transport shows major 
cholesterol pathways between liver and peripheral tissues. Arrows indicate the 
direction of net transport. FC- Free cholesterol, CE- Cholesteryl ester, HDL- High 
density lipoprotein, LVL- Low density lipoprotein, VLDL- Very low density 
lipoprotein (Source: Fielding and Fielding, 1995).  
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 The next essential step of RCT is the delivery of the esterified cholesterols to 
the liver and other steroidogenic tissues. The transfer across membrane is highly 
mediated by cholesterol transporter such as scavenger receptor class B type 1 (SR-
B1) receptor. The SR-B1 receptor located at cell surface membrane of hepatocytes 
facilitates the transfer of CE from HDL into liver. The CEs are transferred from HDL 
to apolipoprotein (apo) B-containing lipoproteins by cholesteryl ester transfer protein 
(CETP) prior to be taken up by RCT terminal via SR-B1. In this process, HDL is not 
been degraded or discarded through enzymatic reactions or endocytosis. In fact, the 
HDL molecule acts as shuttle which delivers the CE to the liver via SR-B1 receptor 
and subsequently returns back to peripheral tissues to transfer more free cholesterol 
to the liver for disposal (Kinoshita et al., 2004; Ono, 2012). 
 
 Excretion of cholesterol from  body is the last step in the RCT route. In liver, 
the transported CE will be converted into bile acid and excreted out from the body. 
The bile reabsorbed in the intestine and secreted along with dietary cholesterol into 
the intestinal lymph, and subsequently reappears in the plasma as chylomicrons. The 
clearance of these chylomicron remnants which conserved most of their cholesterol 
content is rapidly done by the liver. Alternatively, the transported CE is used for 
steroid hormones synthesis in steroidogenic cells (Kocher et al., 2008; Rigotti et al., 
1996).   
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2.2.1  High Density Lipoprotein  
 
 High-density lipoprotein (HDL) has been characterised as heterogeneous 
molecules  and metabolically active group of lipoproteins that exhibits beneficial 
influence on atherosclerosis and subsequently cardiovascular diseases (Davidson and 
Toth, 2007; Linsel and Tall, 2005). The protection of atherosclerosis event by 
functional HDL is through its action in reverse cholesterol transport (Lewis and 
Rader, 2005; Toth, 2003).  
 
 Numerous epidemiological studies have revealed that the level of HDL in 
blood inversely proportional to the incidence of atherosclerosis. A six years 
PROCAM follow-up study demonstrated the incidence of CHD reduces as the 
quantity of HDL-C increases (Assmann et al., 1996) while Framingham Heart Study 
illustrated the risk of CHD lessen with increased level of HDL-C regardless to the 
amount of LDL (Gordon et al., 1977). In addition, many observational studies 
performed globally have confirmed the anti-atherogenic properties of HDL in people 
irrespective of sex, race, or ethnicity (Castelli et al., 1986; Sharrett et al., 2001). HDL 
possesses a range of pleiotropic effects such as anti-inflammatory (Barter et al., 
2002; Cockerill et al., 2001), anti-oxidative (Navab et al., 2000), anti-apoptotic 
(Kimura et al., 2001; Nofer et al., 2001), anti-thrombotic (Epand et al., 1994; 
Viswambharan et al., 2004), vasodilatory (Spieker et al., 2002) and cholesterol 
mobilization properties (Zhang et al., 2003), all of which underlie their potential 
athero-protective nature.  
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 HDL metabolism is a multifaceted mechanism involving HDL synthesis, 
intravascular remodeling and catabolism (Tall, 1990). The concept of reverse 
cholesterol transport closely associates to HDL metabolism clearly explains the task 
of HDL as athero-protective marker and its ability to repress atherosclerosis. HDL 
modulates the lipid homeostasis by mediating selective lipid uptake. Studies carried 
out with labelled HDL clearly explain the athero-protective role of HDL in RCT 
(Pieters et al., 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
[A] 
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2.2.2 Current lipid management therapy on HDL cholesterol 
 
 
 The condition  of dyslipidemia is the key factor resulted in cardiovascular 
disorder especially atherosclerosis in many patients. Besides practicing lifestyle 
changes such as weight reduction, exercise and smoking cessation; advanced 
therapeutic treatments are required to halt the extensive rise of atherosclerotic event. 
 
 Many years ago, the management of atherosclerosis due to dyslipidemia 
started with statin-therapy. Statins have only shown to halt the progression of 
atherosclerosis about 16% (Brewer, 2003). Statins acts by stimulating ATP-binding 
cassette transporter A1 (ABCA1) expression in the hepatic tissues through a liver-
specific promoter element (LPE). This lipid lowering drug reduces the content of 
apolipoprotein (apo) B lipoproteins in the blood stream and eventually decrease the 
rate of CE transfer from HDL by CETP (Le Goff et al., 2004). Moreover, the 
enhancement of hepatic apoA-1 production which triggers by some statins raised the 
nascent HDL in the extracellular region (Schaefer et al., 1999).  
 
 In addition, niacin, a soluble B vitamin is another drug have shown to induce 
the HDL cholesterol levels by 20-30% in clinical trials (Birjmohun et al., 2005). 
Niacin engaged in HDL elevation process via three systems. First, it inhibits the 
hormone sensitive triglyceride lipase which suppress triacylglycerol lipolysis and 
minimize triglyceride level in blood (Karpe and Frayn, 2004). Secondly, niacin 
assists in cholesterol efflux from macrophage to HDL acceptors via ABCA1 
transporters (Rubic et al., 2004). The third mechanism involve the ability of niacin to 
reduce the uptake of HDL particles by the disposal terminals such as liver (Jin et al., 
1997; Shepherd et al., 1979). 
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 Moreover, fibrates, PPARα agonists have shown to elevates the level of HDL 
by up to 10 % only (Birjmohun et al., 2005). The elevation of HDL by fibrates 
involved several steps. Initially, it regulates the expression of apo A-I and apo A-II. 
Then, ABC1 and SR-B1 are up-regulated and control the macrophage cholesterol 
efflux. Finally, the VLDL lipolysis raised by the induced expression of lipoprotein 
lipase (LPL), releasing HDL particles (Chapman, 2003; Fruchart et al., 2001).  
 
 Other than these, triazolidinediones (Raskin et al., 2001), JTT-705 (Okamoto 
et al., 2000) and Torcetrapib (Clark et al., 2006) have been also reported on their 
ability to increase the level of HDL cholesterols at lower level. The actions of 
currently available drugs in enhancing the HDL cholesterol are considered 
inadequate as there is still remain a larger burden of residual risk of CHD lacking 
solution around the world. 
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2.3 Scavenger Receptor Class B Type 1 (SR-B1) 
 
 
 
 Scavenger Receptor Class B Type 1 (SR-B1) is a 509 amino acid, ~82kDa 
cell surface glycoprotein belongs to CD36 family. SR-B1 contains two cytosolic 
regions flanking at N and C terminus.  Initially, human SR-B1 (hSR-B1) identified as 
a protein with unknown function called CLA-1 and mapped to human chromosome-
12. There is two E-box consensus sequences located on hSR-B1 promoter region, 
one at proximal (-160bp) and the other is at distal (-1145bp) to the transcription start 
site (Cao et al., 1997). SR-B1 protein embedded in the plasma membrane via two 
transmembrane domains. This receptor expressed abundantly in liver, adrenal gland, 
ovary and testis. The hSR-B1 exhibits tissue-specific pattern expression. Unlike 
scavenger receptor class A and C, the binding specificity of this receptor to various 
lipoprotein in variety of cell types and tissues is very unique (Acton et al., 1996; Cao 
et al., 1997; Landschulz et al., 1996). 
 
2.3.1 SR-B1 as anti-atherosclerotic receptor 
 
 SR-B1 is a multi-ligand receptor closely associated to cholesterol 
homeostasis. The discovery of SR-B1 as HDL receptor has advocated the interest to 
investigate its potential role in HDL metabolism and the significance relevance in 
atherosclerosis. SR-B1 represent as an anti-atherosclerotic receptor plays an 
important role in RCT and therefore may eventually attenuates the incidence of CHD 
(Kocher et al., 2008). The selective uptake of cholesterol by HDL is merely 
stimulated by the expression of SR-B1 receptors and provide protection against 
atherosclerosis by being a key regulator in RCT (Rigotti et al., 1997). Studies have 
demonstrated that SR-B1 possesses athero-protective activity (Arai et al., 1999). For 
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example, investigation carried out using animal model showed that over expression 
of SR-B1 suppresses atherogenesis in LDL receptor knock-out mice and the 
combined inactivation of the apo-E and SR-B1 genes in mice results in dramatically 
enhanced aortic root atherogenesis compared to apo-E knock-out mice (Kocher et al., 
2008). There is another study illustrated SR-B1's essential role in selective 
cholesterol transport, balancing the plasma lipoprotein and biliary cholesterol levels, 
HDL structure remodeling and RCT (Trigatti et al., 1999). As well, the central role 
of SR-B1 in hepatic selective uptake of HDL cholesterol was clearly established 
(Varban et al., 1998). 
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2.3.2 Transcriptional regulation of SR-B1 expression in liver 
 
 Numerous studies have scientifically proven the regulation of hepatic SR-B1 
expression at transcriptional level by various potential molecules. A number of 
nuclear factors (PPAR, LXR, FXR, SF-1, LRH-1, estrogen receptors and SREBPs) 
and stimulation of some intracellular metabolic pathways via some potential ligands 
(IGF-1, glucose, leptin, inflammatory agents, vitamin A and synthetic compounds) 
are able to modulate the SR-B1 mRNA level. Indeed, the consensus sequences of 
some of these nuclear response elements motifs which are responsible for the 
interaction  with SR-B1 have been identified in the promoter region of human and rat 
SR-B1 (Figure 2.3) (Rhainds and Brissette, 2004). 
 
 A few peroxisome proliferator-activated receptors (PPAR) ligands such as 
fatty acids, fibrates and glitazones have shown to involve in SR-B1 gene regulation. 
A marked increase in SR-B1 mRNA and protein expression observed in hamster fed 
with high contain of fatty acid diet (Spady et al., 1999). Similarly, treatment with 
selective PPARγ and PPARα agonists induced hepatic SR-B1 expression in-vivo and 
in-vitro respectively (Lopez and McLean, 2006; Malerod et al., 2003). In addition, 
Malerod et al., (2002) demonstrated liver X receptors (LXR) participation in 
controlling SR-B1 expression. LXR stimulation by oxysterols enhanced SR-B1 
expression and concurrently mediates cholesterol excretion via bile synthesis. A 
recent study showed that the activation of farnesoid X receptors (FXR) by its 
appropriate agonist elevates SR-B1 expression in association with changes in hepatic 
regulatory factors (Zhang et al., 2010). Besides, the expression of SR-B1 was 
diminished in the liver of FXR deficiency mice (Lambert et al., 2003).  
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Figure 2.3  Graphical representation of important regulatory and structural elements 
in rat and human SR-B1 promoter region. Black triangles and numbers indicate 
nucleotide position relative to translation initiation codon (Source: Rhainds and 
Brissette, 2004). 
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Finally, in-vitro and in-vivo studies have exemplified the positive regulation of SR-
B1 by liver receptor homolog-1 (LRH-1) (Schoonjans et al., 2002). In contrast, 
fibrates administration leads to a drop in SR-B1 protein level in the liver of 
experimental mice (Mardones et al., 2003). Other than these, estrogen treatment and 
sterol regulatory element binding proteins (SREBPs) are also possesses regulatory 
effects on hepatic SR-B1 expression (Horton et al., 2003; Lopez and McLean, 1999). 
 
 Likewise, the activation of secondary messenger pathways by some 
endogenous and exogenous compounds also modulate the SR-B1 expression in 
hepatocytes. The endogenous compounds such as insulin-like growth factor-1 (IGF-
1) (Cao et al., 2004), glucose (Murao et al., 2008) and few pro-inflammatory agents 
showed activation of hepatic SR-B1 mRNA level. Leptin, an adipokine have shown 
up-regulation of SR-B1 at mRNA and protein level which initially modulating the 
overall energy metabolism (Lundasen et al., 2003). Interestingly, vitamin A, an 
exogenous compound significantly raised SR-B1 expression in the liver and 
subsequently an increased quantity of SR-B1 protein and decreased level of HDL 
cholesterol were observed in the obese phenotypes (Jeyakumar et al., 2007). 
Moreover, some synthetic lipid lowering compounds (Lukic et al., 2003; Mendez-
Gonzalez et al., 2010) and isoflavones such as pratensein (Yang et al., 2009) have 
been also reported on their abilities to up-regulate SR-B1 mRNA expression and 
enhanced the uptake of HDL cholesterol. Recently, trichostatin A (TSA); a synthetic 
compound has been described on facilitating trans-activation of SR-B1 promoter 
activity and boost the protein expression in hepatic cell cultures (Bao et al., 2009). 
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2.3.3 Post-transcriptional regulation of SR-B1 expression in liver 
 
 
 
 Beside transcriptional control, the post- transcriptional regulation of SR-B1 
have also been reported. The down-regulation and up-regulation of SR-B1 protein 
expression is facilitated by various natural products and synthetic drugs.  
 
 Particularly, some hormones and pharmacological agents potentially drive the 
post-transcriptional up-regulation of SR-B1. Thyroid hormones such as 
triiodothyronin (T3) and tetraiodothyronine (T4) have shown to induce the hepatic 
SR-B1 proteins as well as other proteins involves in cholesterol homeostasis 
(Johansson et al., 2005; Tancevski et al., 2010). On the other hand, insulin treatment 
enhances the SR-B1 protein bioavailability in the liver by promoting translocation of 
the protein receptor via P13K pathway. The raised expression of SR-B1 receptors on 
hepatic cell surfaces due to insulin, improves HDL mediated- cholesterol efflux 
without concomitant changes in SR-B1 gene expression (Shetty et al., 2006). 
Interestingly, phosphatidylethanolamine N-methyltransferase (PEMT); a liver 
specific enzyme shows an inverse relation of the post-transcriptional expression of 
SR-B1. Hence, the enzymatic dysfunction of PEMT leads to induction of SR-B1 
protein expression regardless of unchanged mRNA level (Robichaud et al., 2008).  
 
 On the contrary, action of some hormones, vitamin and synthetic compounds 
leads to down-regulation SR-B1 protein expression in the liver without simultaneous 
effect on the gene expression. Treatment of 17β- estradiol on human hepatocytes and 
estrogen supplemented animal model demonstrated suppression of SR-B1 protein 
receptors (Zhang et al., 2007). In addition, another in-vivo and in-vitro studies 
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implied vitamin E as supplement resulted in reduction of hepatic SR-B1 protein level 
(Keaney et al., 1999; Witt et al., 2000). The usage of fibrates, a synthetic PPARα 
ligand associated with a significant drop in SR-B1 protein in the liver without any 
modifications of mRNA level. It was demonstrated that this drug disturbed the 
protein stability in the peripheral membrane and led to degradation (Lan and Silver, 
2005; Mardones et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
